Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis.
James YarmolinskyVirginia Díez-ObreroTom G RichardsonMarie PigeyreJennifer SjaardaGuillaume ParéVenexia M WalkerEmma E VincentVanessa Y TanMireia Obon-SantacanaDemetrius AlbanesJochen HampeAndrea GsurHeather HampelRish K PaiMark E JenkinsSteven GallingerGraham CaseyQuan LongChristopher Ian Amosnull nullnull nullnull nullGeorge Davey SmithRichard M MartinVictor MorenoPublished in: PLoS medicine (2022)
In this study, we observed that genetically proxied long-term ACE inhibition was associated with an increased risk of colorectal cancer, warranting comprehensive evaluation of the safety profiles of ACE inhibitors in clinical trials with adequate follow-up. There was little evidence to support associations across other drug target-cancer risk analyses, consistent with findings from short-term randomized controlled trials for these medications.